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The present study examined the cell surface proteome of human periodontal ligament stem cells (PDLSC) compared to human
fibroblasts. Cell surface proteins were prelabelled with CyDye before processing to extract the membrane lysates, which were
separated using 2D electrophoresis. Selected differentially expressed protein “spots” were identified usingMass spectrometry. Four
proteins were selected for validation: CD73, CD90, Annexin A2, and sphingosine kinase 1 previously associated with mesenchymal
stem cells. Flow cytometric analysis found that CD73 andCD90were highly expressed by humanPDLSC and gingival fibroblasts but
not by keratinocytes, indicating that these antigens could be used as potentialmarkers for distinguishing betweenmesenchymal cells
and epithelial cell populations. Annexin A2 was also found to be expressed at low copy number on the cell surface of human PDLSC
and gingival fibroblasts, while human keratinocytes lacked any cell surface expression of Annexin A2. In contrast, sphingosine
kinase 1 expression was detected in all the cell types examined using immunocytochemical analysis. These proteomic studies
form the foundation to further define the cell surface protein expression profile of PDLSC in order to better characterise this cell
population and help develop novel strategies for the purification of this stem cell population.
1. Introduction
Despite encouraging outcomes, therapeutic utilization of
mesenchymal stem cells (MSC) is constrained by the lack of
understanding and definition of their properties and devel-
opmental status following ex vivo expansion. Heterogeneity
inherent within progenitor populations presents as one of the
major limitations to their clinical application in regenerative
medicine. The variability and inconsistencies in cellular
properties allude to a hierarchical order within stem cell
populations and result in the coexistence of subsets of distinct
morphologies, phenotypes, proliferation rates, and biological
functions [1–3]. Currently, there is a lack of individual or a set
ofmarkers that can distinguish different subsets withinMSC-
like populations of different origins from more differentiated
fibroblastic cells in any tissue.
Identification of stem/progenitor cells residing in the
periodontium [4–6] has offered a potential novel therapeutic
avenue for treating periodontal tissues damaged due to
trauma, injury, and disease. Periodontal diseases are highly
prevalent among all human populations and if untreated
cause the destruction of periodontal supporting tissues and
can potentially result in tooth loss. Predictable regeneration
of periodontal tissues as a result of advanced periodontal
diseases is beyond the scope of current technologies and,
therefore, alternative strategies are being investigated.
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In addition to periodontal ligament stem cells (PDLSC),
the periodontium contains multiple cell types including
fibroblasts, endothelial cells, epithelial cell rests of Malassez
(ERM), osteoblasts, and cementoblasts [7]. This array of
specialised cell types is integrated into and cofunctions to
provide the periodontiumwith its essential and unique struc-
tural and mechanical properties. This biological complexity
and cellular heterogeneity highlights the need for identifi-
cation of surface markers specific to each cell subset within
the periodontium to enable identification and discriminant
isolation of desired and required cell populations.
It has been demonstrated that PDLSC share a phenotypic
profile characteristic of bone marrow derived mesenchymal
stem cells (BMSC) including expression of BMSC markers
CD29, CD44, CD90, and CD105 [8]. Furthermore, PDLSC
express the early BMSC and perivascular cell surface markers
STRO-1 and CD146/MUC18 [4], with a subset of progenitors
presenting with other antigens associated with perivascular
tissues (alpha-smooth muscle actin and pericyte-associated
antigen, 3G5) [9]. Together, these findings designate a pos-
sible perivascular origin of PDLSC, in accord with earlier
findings by McCulloch and colleagues [10, 11]. In con-
junction, comparative genomic analyses identified unique
features exhibited by PDLSC when compared to BMSC and
dental pulp stem cells (DPSC). These studies demonstrated
increased levels of scleraxis (a tendon-specific transcription
factor) [4] and PLAP-1 (periodontal ligament associated
protein-1/asporin) expression in PDLSC [12]. A panel of
markers, proposed for the current identification of PDLSC,
includes alkaline phosphatase, type I collagen, periostin,
runt-related transcription factor-2 (Runx2), and epithelial
growth factor receptor, which are also expressed by BMSC,
considering that both cell populations commonly hold the
innate capacity for formation of mineralized matrix in the
form of cementum and bone, respectively [13]. Since the cell
surface markers described above are ubiquitously expressed
byMSC-like populations derived from all dental tissues, spe-
cific cell surface antigens, capable of distinguishing between
individual dental stem cell population subsets, are yet to
be identified [14]. Therefore, our understanding of the cell
surface phenotype of PDLSC falls short when considering
the need to isolate and purify stem/progenitor cell subsets
from the heterogeneous PDL population. This has driven
the use of proteomics, the technology investigating global
protein expression, to characterise the cell surface phenotype
of PDLSC.
Proteomic studies investigating dental tissues have been
summarized byMcCulloch [15].While themajority of studies
focused on protein expression by periodontal microbiota
[16–18], a limited number of papers examined proteomic
profiles of periodontal ligament cells and tissues [15]. In this
study, we provide an insight into the cell surface proteome of
PDLSC to identify potential discriminatory PDLSC markers
not expressed by other cells residing in the periodontium.
2. Methods and Materials
2.1. Isolation of Human PDLSC and Gingival Fibroblasts.
Human PDLSC and gingival fibroblasts (GF) were isolated
from three donors and cultured as previously described
(Human Research Ethics Committee of the University of
Adelaide, Approval Number H-112-2008) [4, 19]. Briefly,
gingival and periodontal ligament tissues were collected from
excised gingiva andmiddle third of the root, respectively.The
tissues were digested in equal volumes of collagenase type
I (3mg/mL; Worthington Biochemical, Lakewood, NJ) and
dispase type II (4mg/mL; Roche Diagnostics, Indianapolis,
IN) for 2 hours at 37∘C. Isolated cells were maintained
and cultured in modified 𝛼-MEM media (𝛼-MEM; Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% FCS
(Thermo Electron, Melbourne, VIC, Australia), 50U/mL
and 50𝜇g/mL penicillin and streptomycin (Sigma-Aldrich),
1mM sodium pyruvate, 2mM L-glutamine (SAFC, Lenexa,
KS, USA), and 100 𝜇ML-ascorbate-2-phosphate (Novachem,
Melbourne, VIC, Australia) at 37∘C and 5%CO
2
in a humidi-
fied environment, with a twice-weekly medium change. Cells
were harvested and further expanded once upon reaching
confluence. This process was repeated when cells reached
80% confluence until desired cell numbers were obtained.
Human neonatal foreskins, collected from routine cir-
cumcisions, were used to isolate epithelial sheets after over-
night incubation with 4mg/mL dispase at 4∘C, followed by
trypsinization for 5min at 37∘C to obtain basal keratinocytes.
Keratinocytes were cultured in DMEM containing 10%
fetal calf serum, 20 ng/mL epidermal growth factor (Sigma-
Aldrich), and 0.4 𝜇g/mL hydrocortisone (Sigma-Aldrich), at
37∘C and 5%CO
2
in a humidified environment, with a twice-
weekly medium change.
2.2. Immunohistochemistry. Chamber slides (Nalge-Nunc
Lab-Tek, Rochester, NY, USA) were seeded with 8 × 103 cells
per cm2, in media with additives for 2 days. The slides
were fixed with 4% paraformaldehyde (PFA) and endoge-




in methanol. The sections were incubated with primary
antibodies or isotype control antibodies overnight at 4∘C,
secondary antibodies for 1 hour at room temperature, Vec-
tastain ABC Reagents (Vector Laboratories, Burlingame, CA,
USA) according to the manufacturer’s recommendations,
or horseradish-peroxidase-labelled streptavidin (Promega,
Madison, WI, USA) at 1 in 1000 dilution and then developed
with diaminobenzidine (Dako, Campbellfield, VIC, Aus-
tralia). The slides were counterstained briefly with haema-
toxylin (ProSciTech, Thuringowa Central, QLD, Australia).
Antibodies used in this study are 1B5, mouse IgG1 isotype
control (1 : 25; Professor L. K. Ashman, University of New-
castle, NSW, Australia); mouse IgG1 anti-humanCD73 (1 : 25;
BD Pharmingen, Sparks,MD,USA);mouse IgG1 anti-human
CD90 (1 : 25; BD Pharmingen); mouse IgG1 anti-human
Annexin A2 (1 : 12.5; Invitrogen, Waltham, MA, USA); rabbit
anti-human sphingosine kinase 1 (1 : 20; Cayman Chemical,
Ann Arbor, MI, USA); normal rabbit Ig (1 : 20; Vector
Laboratories, Burlingame, CA, USA); goat anti-mouse IgG
biotin secondary antibody (1 : 200; Southern Biotechnology
Associates, Birmingham, AL); and goat anti-rabbit IgG biotin
secondary antibody (1 : 150; Vector Laboratories).
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2.3. Immunophenotypic Profiling. Single cell suspensions of
2 × 105 cells were blocked with 5% FCS, 1% bovine serum
albumin (BSA, SAFC), 50U/mL penicillin, 50 𝜇g/mL strep-
tomycin, and 5% normal human serum (Red Cross, SA,
Australia) in HBSS on ice. Cells were treated with primary or
isotype control antibodies (CD73, CD90, and Annexin A2)
at a concentration of 20𝜇g/mL, followed by incubation with
phycoerythrin (PE) conjugated goat anti-mouse IgG1 (1 : 50;
Southern Biotechnology Associates). Samples were fixed in
PBS with 0.1% formalin and 20mg/mL glucose. Analysis was
performed on a fluorescence-activated cell sorter fitted with
250MW argon laser (Beckman Coulter Cytomics FC500,
using CXP Cytometry List Mode Data Acquisition and
Analysis Software version 2.2; Beckman Coulter, Miami, FL,
USA).
2.4. Proteomic Analysis. All equipment and reagents were
purchased from Bio-Rad Laboratories (Hercules, CA, USA)
unless stated otherwise. CyDye DIGE Fluor minimal dye was
purchased from GE Healthcare (Buckinghamshire, UK).
2.5. Cell Surface Labelling Using CyDye DIGE Fluor Minimal
Dye. CyDye fluorescent cell surface protein labelling was
performed as previously reported [4, 20]. Briefly, approxi-
mately 20 million subconfluent PDLSC or GF were detached
with either 1mM PUCK’s EDTA or 3mg/mL type I colla-
genase and aliquoted into ∼5 million cells per tube. Cells
were washed in ice cold HBSS (pH 7.4) followed by ice cold
HBSS (pH 8.5) and centrifuged at 800×g for 2 minutes.
The cell pellets were resuspended in 200 𝜇L labelling buffer
containing HBSS (pH 8.5) and 1M urea. Cells were then
labelled with 600 pmol of either Cy2, Cy3, or Cy5 or CyDye
DIGE Fluor minimal dyes on ice in the dark for 20 minutes.
Staining was quenched by adding 20 𝜇L lysine (10mM) for
10 minutes. Surface-labelled cells were pelleted by centrifu-
gation and resuspended in 202𝜇L HBSS (pH 7.4). An aliquot
(2 𝜇L) was taken prior to and after labelling to check for
labelling efficiency using flow cytometry.
2.6. Membrane Protein Enrichment. Proteins were isolated
and fractionated using a phase separation kit (Mem-PER,
Pierce, Rockford, IL, USA) according to the manufacturer’s
instructions. Briefly, 150 𝜇L reagent A containing 1 𝜇L pro-
tease inhibitor (Sigma) was added to cell pellets contain-
ing PDLSC or GF. Following 10-minute incubation, 450 𝜇L
mixture of reagents B and C was added to cell lysates and
tubes were kept on ice for 30 minutes. The preparation
was centrifuged at 10,000×g for 3 minutes, at 4∘C, and
the supernatant was incubated at 37∘C for 20 minutes.
Following centrifugation at 10,000×g and phase separation,
the hydrophobic fraction containing membrane proteins
was carefully removed and purified using ReadyPrep 2-D
Cleanup Kit. Membrane protein enrichment efficiency was
assessed and cells were subjected to up to three membrane
fractionation steps.
2.7. Membrane Protein Separation by Two-Dimensional Gel
Electrophoresis (2DE). Membrane proteins were solubilised
Table 1: IEF conditions for 11 cm IPG (3–10).
Step number Voltage Voltage ramping mode Time
Step 1 150V Linear 1 hour
Step 2 300V Linear 2.30 hours
Step 3 600V Linear 1.50 hours
Step 4 1200V Linear 1.50 hours
Step 5 4000V Slow 1.50 hours
Step 6 8000V Slow 1 hour
Step 7 8000V Linear 30000 volt-hours
Step 8 500V Slow 0.15 hours
with ReadyPrep reagent 3 buffer for 1 hour at room tem-
perature. The protein was solubilised by gentle aspiration
through a fine-gauge needle, as previously described by Zilm
et al. [21]. The protein concentration was determined using
RC/DC Protein Assay Kit according to the manufacturer’s
instructions. Proteins were separated in the first dimension
using 11 cm immobilised pH gradient (IPG) strips (pH 3–10)
which had been passively rehydrated for 24 hours in 330𝜇L
rehydration/extraction buffer #3, containing 0.2% (w/v) pH
3–10 ampholytes and 1.2% (v/v) De-Streak Reagent (GE
Healthcare, Buckinghamshire,UK). IEFwas performedusing
a Protean IEF cell. Briefly, membrane protein preparations
containing 150 𝜇g protein were cup-loaded onto the anode
end of the IPG strip. The IEF cycle consisted of 8 steps
outlined in Table 1, with a 50𝜇A/strip current limit, and the
temperature was maintained at 20∘C. Duplicate IPG strips
were run concurrently. Following IEF, the IPG strips were
equilibrated as previously described [22]. Polyacrylamide gels
(18×18 cm) containing 8% T, 3.3% C, 0.1% SDS, and 375mM
Tris/HCl (pH 8.8) were cast without stacking gels using a
Protean II XL casting chamber. Proteins were separated in the
second dimension using a Protean II XL Multicell (Bio-Rad
Laboratories) in tris-glycine tank buffer (25mMTris, 192mM
glycine, and 0.1% (w/v) SDS) and resolved at 7mA/gel.
2.8. Gel Visualisation. Gels were scanned using a Typhoon
Trio Variable Mode Imager (Molecular Dynamics Inc.,
Sunnyvale, CA) with a pixel resolution of 100 𝜇m at the
CyDye excitation and emission wavelengths described by
the manufacturer. Image analysis was performed using PD-
Quest software (version 7.2, Bio-Rad Laboratories). Replicate
groups, each containing four gels, were used for analysis.
Protein spots were automatically detected and manually
edited. Gel staining was normalized using the total density
in gels.
2.9. Flamingo Fluorescent Staining. To visualise all proteins,
gels were fixed in 40% ethanol (v/v)/10% acetic acid (v/v)
in Milli-Q water and stained with Flamingo Fluorescent
Stain (Bio-Rad Laboratories) according to themanufacturer’s
instructions. Gels were destained in 0.1% (v/v) Tween 20 in
Milli-Q water for 10 minutes prior to imaging. Gels were
scanned using a Typhoon Trio Variable Mode Imager using
a green laser (532 nm) excitation source and 610 ± 30 nm
bandpass emission filter.
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2.10. Automated Spot Picking. Gel images were scanned
using a Typhoon Trio Variable Mode Imager and imported
into DeCyder software (version 6.5, GE Healthcare) and
spots were detected using the automated method. Spots of
interest were selected to generate a pick-list. The pick-list
was exported from DeCyder and imported into Spot Picker
software (version 1.2, GE Healthcare). Spots were excised
using the Ettan Spot Cutting Robot (GE Healthcare) accord-
ing to themanufacturer’s instructions. Gel plugs were washed





followed by Milli-Q water, then dehydrated in acetonitrile
(ACN), and dried.
2.11. Protein Identification by Liquid Chromatography-Electro-
spray Ionisation-Ion Trap (LC-ESI-IT) Mass Spectrometry
(MS). Each gel plug was digested with 10 𝜇L of 5mM ammo-
nium bicarbonate with 10% ACN containing 100 ng trypsin
(Promega) for 16 hours at 37∘C. Peptides were extracted
sequentially with 1% formic acid (FA), 50% ACN/0.1% FA,
and ACN, and the combined extracts were concentrated by
centrifugal evaporation and diluted in 6 𝜇L 3% ACN/0.1%
FA. Vacuum concentrated samples were resuspended in 0.1%
FA in 2% ACN to a total volume of ∼8 𝜇L. LC-ESI-IT
MS/MS was performed using an online 1100 series HPLC
system (Agilent Technologies) and HCT Ultra 3D-Ion Trap
mass spectrometer (Bruker Daltonics). The LC system was
interfaced to the MS using an Agilent Technologies Chip
Cube operating with a ProtID-Chip-150 (II), which integrates
the enrichment column (Zorbax 300SB-C18, 4mm, 40 nL),
analytical column (Zorbax 300 SB-C18, 150mm × 75𝜇m),
and nanospray emitter. 5 𝜇L samples were loaded onto the
enrichment column set at a flow rate of 4𝜇L/min in Mobile
Phase A (0.1% FA in 2% v/v ACN) and resolved with 1–30%
gradient of Mobile Phase B (0.1% FA in 98% w/v ACN) over
32 minutes at 300 nL/min. Ionizable species (300 < m/z <
3,000) were trapped and the two most intense ions eluting at
the time were fragmented by collision-induced dissociation.
Active exclusion was used to exclude a precursor ion for 30
seconds following the acquisition of two spectra.
2.12. Protein Identification Using Web-Based Bioinformatics
Tools. MS and MS/MS spectra were subjected to peak
detection and deconvolution using Data Analysis (version
3.4, Bruker Daltonics, Billerica, MA, USA). Compound lists
were exported into BioTools (version 3.1, Bruker Daltonics)
and then submitted to Mascot (version 2.2, Boston, MA,
USA) using the following parameters: fixed modification =
carbamidomethyl (C), variablemodification = oxidation (M),
MSmass tolerance = 1.5Da, MS/MSmass tolerance = 0.8Da,
peptide charge = 1+, 2+, or 3+, andmissed cleavages = 3. Data
were matched to the Swiss-Prot protein database.
3. Results
3.1. Membrane Protein Expression of Ex Vivo Expanded Hu-
man PDLSC. CyDye-tagged membrane-associated proteins
derived from human PDLSC following ex vivo expansion
were separated by 2-dimensional electrophoresis. Based on
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Figure 1: Representative raw 2DE gel of CyDye labelled proteins of
ex vivo expanded human periodontal ligament stem cells and the
location of proteins identified on the raw 2DE image. Following cell
surface labelling with CyDye and membrane protein enrichment,
proteins were separated by 2DE using a pI range of pH 3–10 and a
molecular weight range of 10–110 kDa. Following image analysis, 80
well-resolved protein spots were detected. A total of 32 membrane-
associated protein spots were consistently found on replicate gels.
with a molecular weight range of 10–110 kDa were detected
after automatic exclusion of pseudospots and the locations of
the identified protein spots on the representative raw image
are shown in Figure 1.
3.2. Identification of Proteins Expressed by Human PDLSC.
Following spot excision and analysis by mass spectrometry,
a total of 32 protein spots were identified as membrane-
associated proteins (Figure 1). Table 2 outlines the details
of the membrane-associated proteins, including the protein
name, spot number, predicted molecular weight and pI
values, ID/total queries, combined ion scores, and coverage.
Some proteins were identified in multiple spots (e.g., 5󸀠-
nucleotidase, Annexin A2, and sphingosine kinase 1) sug-
gesting the presence of isoforms, possibly as a result of
posttranslational modifications. Differences in the observed
molecular weight/pI and the expected values were observed
in some proteins (e.g., sphingosine kinase 1), possibly due
to posttranslational modifications, proteolysis, or protein
aggregation. Importantly, this approach was validated by
the identification of MSC-associated stem cell surface pro-
teins, 5󸀠-nucleotidase (CD73) andThy-1membrane glycopro-
tein (CD90), previously shown to be expressed by PDLSC
[8]. Furthermore, MS identified other membrane-associated
markers, such as Annexin A2 and sphingosine kinase 1, the
expression of which had not previously been reported by
human PDLSC. All four proteins were chosen for further
confirmatory analyses.
3.3. Validation of the Expression of 5󸀠-Nucleotidase, Thy-1
Membrane Glycoprotein, Annexin A2, and Sphingosine Kinase
1. To confirm the expression of selected proteins including
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Table 2: Membrane-associated proteins on human PDLSC.
Swiss-Prot 57.7












1A01 HUMAN HLA class I histocompatibilityantigen, A-1 alpha chain 243 41.1/6.1 2/612 66 10
1C06 HUMAN HLA class I histocompatibilityantigen, Cw-6 alpha chain 239 41.4/5.7 4/638 175 18
5NTD HUMAN 5󸀠-Nucleotidase
78 63.9/6.6 13/518 287 17
80 63.9/6.6 8/513 206 11
90 63.9/6.6 41/546 872 32
99 63.9/6.6 13/535 191 15
101 63.9/6.6 39/517 945 38
103 63.9/6.6 42/539 933 33
109 63.9/6.6 25/536 606 22
111 63.9/6.6 2/558 34 6
326 63.9/6.6 53/544 961 35
86 63.9/6.6 25/356 521 31
97 63.9/6.6 45/414 1044 39
AMPB HUMAN Aminopeptidase B 94 73.2/5.5 5/559 172 10
ANXA2 HUMAN Annexin A2
285 38.8/7.6 36/581 489 47
288 38.8/7.6 87/585 1907 67
289 38.8/7.6 56/600 950 55
292 38.8/7.6 3/594 76 11
304 38.8/7.6 14/536 241 28
CAP2 HUMAN Adenylyl cyclase-associatedprotein 2
154 53.1/6.0 2/576 67 6
156 53.1/6.0 4/557 102 8
165 53.1/6.0 3/619 102 11
CO1A1 HUMAN Collagen alpha-1(I) chain 292 139.9/5.6 7/594 103 4
CO6A3 HUMAN Collagen alpha-3(VI) chain 20 345.2/6.3 9/568 159 3
DNJA1 HUMAN DnaJ homolog subfamily Amember 1 208 45.6/6.6 4/521 95 12
EHD3 HUMAN EH domain-containing protein 3 139 62.0/6.1 4/600 71 8
EZRI HUMAN Ezrin 65 69.5/5.9 28/558 455 26
FLNC HUMAN Filamin-C
29 293.4/5.6 4/492 49 2
78 293.4/5.6 3/518 65 1
139 293.4/5.6 14/600 363 6
147 293.4/5.6 13/525 237 4
191 293.4/5.6 4/586 147 2
GELS HUMAN Gelsolin 46 86.0/5.9 46/636 1011 35
K2C1 HUMAN Keratin, type II cytoskeletal 1
25 66.2/8.2 5/578 128 9
46 66.2/8.2 11/636 456 17
47 66.2/8.2 7/491 170 7
80 66.2/8.2 11/513 227 13
91 66.2/8.2 3/666 94 12
94 66.2/8.2 4/559 146 8
98 66.2/8.2 2/639 57 7
104 66.2/8.2 2/520 80 3
111 66.2/8.2 5/558 79 10
130 66.2/8.2 3/614 60 8
147 66.2/8.2 20/525 256 13
153 66.2/8.2 2/615 126 7
154 66.2/8.2 3/576 107 8
228 66.2/8.2 10/664 466 22
289 66.2/8.2 14/600 386 15
292 66.2/8.2 2/594 55 3
324 66.2/8.2 5/570 127 10
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Table 2: Continued.
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KAP2 HUMAN cAMP-dependent protein kinasetype II-alpha regulatory subunit 178 45.8/5.0 13/621 360 22
NOMO2 HUMAN Nodal modulator 2
19 140.4/5.5 9/599 244 8
20 140.4/5.5 10/568 189 12
25 140.4/5.5 10/578 226 8
27 140.4/5.5 11/583 224 10
28 140.4/5.5 11/436 244 12
NUCB2 HUMAN Nucleobindin-2 178 50.3/5.0 3/621 100 5
PDIA6 HUMAN Protein disulfide-isomerase A6 175 48.5/5.0 6/592 209 12178 48.5/5.0 7/621 278 10
RUVB2 HUMAN RuvB-like 2 191 51.3/5.5 25/586 614 34
SBP1 HUMAN Selenium-binding protein 1 165 52.9/5.9 7/619 126 8
SNX4 HUMAN Sorting nexin-4 155 52.2/5.7 5/637 157 14
SPHK1 HUMAN Sphingosine kinase 1
19 42.9/6.6 12/599 253 18
20 42.9/6.6 5/568 188 16
21 42.9/6.6 4/518 138 11
34 42.9/6.6 3/517 200 11
STML2 HUMAN Stomatin-like protein 2 239 38.6/6.9 13/638 584 37240 38.6/6.9 6/656 266 27
STXB3 HUMAN Syntaxin-binding protein 3 111 68.6/8.0 5/558 97 7118 68.6/8.0 6/479 103 7
SWP70 HUMAN Switch-associated protein 70 94 69.4/5.7 3/559 80 599 69.4/5.7 6/535 136 7
THY1 HUMAN Thy-1 membrane glycoprotein 304 18.2/9.0 3/536 55 16
UBP14 HUMAN Ubiquitin carboxyl-terminalhydrolase 14
130 56.5/5.2 6/614 176 15
132 56.5/5.2 8/611 184 18
133 56.5/5.2 3/635 100 5
136 56.5/5.2 15/642 372 24
ULA1 HUMAN NEDD8-activating enzyme E1regulatory subunit 133 60.7/5.2 6/635 127 8
VATB2 HUMAN V-type proton ATPase subunit B,brain isoform
153 56.8/5.6 4/615 191 12
154 56.8/5.6 9/576 252 14
155 56.8/5.6 7/637 300 16
VDAC1 HUMAN Voltage-dependentanion-selective channel protein 1
300 30.9/8.6 7/601 128 18
304 30.9/8.6 34/536 902 59
305 30.9/8.6 19/524 319 38
VIME HUMAN Vimentin
130 53.7/5.1 2/614 68 6
161 53.7/5.1 28/626 710 46
175 53.7/5.1 44/592 1026 63
178 53.7/5.1 46/621 1306 58
222 53.7/5.1 3/630 87 6
228 53.7/5.1 5/664 139 9
239 53.7/5.1 4/638 139 9
240 53.7/5.1 5/656 169 12
VINC HUMAN Vinculin
25 124.3/5.5 14/578 226 16
27 124.3/5.5 30/583 643 25
CD73, CD90, Annexin A2, and sphingosine kinase 1 (SPK1),
additional studies were performed to investigate their expres-
sion in human PDLSC, GF, and keratinocytes (epithelial
cell population). Flow cytometric analysis demonstrated high
surface expression of CD73 and CD90 and low cell surface
levels of Annexin A2 expression in human PDLSC and
GF populations (Figure 2). In contrast, human keratinocytes
showed a lack of cell surface expression for CD73, CD90,
and Annexin A2 (Figure 2). Table 3 summarizes levels of
surface expression of these four antigens on assessed cell
types. In summary, CD73 and CD90 were expressed by
human PDLSC and GF, but not by human keratinocytes,
confirming that they are MSC-associated markers. Annexin
A2 was demonstrated to be expressed at low levels by human
Stem Cells International 7




































































































































































































































Figure 2: Validation of surface expression of CD73, CD90, andAnnexin A2 using flow cytometric analysis in human (a) periodontal ligament
stem cells, (b) gingival fibroblasts, and (c) skin keratinocytes.
PDLSC (1.92–7.83%) and human GF (2.41–4.66%), while
human keratinocytes were largely negative for Annexin A2
expression (0.88–1.64%). Previous studies have shown that
SPK1 can translocate to the plasma membrane upon cell
stimulation by cytokines [23–29]. No positive expression was
detected with the anti-SPK1 antibody to the human cell types
by flow cytometric analysis (data not shown), most likely
because the available antibody reagent did not react with the
extracellular domain of SPK1.
Additional studies were performed to investigate the
expression of Annexin A2 and SPK1 in human PDLSC,
GF, and keratinocytes, using immunocytochemistry. All cell
types studiedwere positive to anti-AnnexinA2 and anti-SPK1
antibodies (Figure 3). Of note, no reactivity was observed
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Table 3: Flow cytometric analysis of cell surface expression of CD73,
CD90, and Annexin A2. Data represent median% (range); 𝑛 = 3
replicate experiments.
Antigen PDLSC GF Keratinocytes
CD73 99.90 99.97 0.82
(99.4–99.9) (99.9–100) (0.78–0.84)
CD90 99.98 99.98 1.58
(99.8–100) (99.9–100) (1.55–1.62)
Annexin A2 4.48 2.92 0.86
(1.92–7.83) (2.41–4.66) (0.86–1.64)
with the anti-CD73 or anti-CD90 antibodies to all cell types
examined (data not shown), indicating that the specific
epitopes identified by these antibodies were compromised
following processing for immunocytochemical analysis.
4. Discussion
Initially, the first proteomic reference map of undifferenti-
ated periodontal ligament fibroblasts identified 117 proteins,
consistently expressed across three clones, which included
a variety of expected cytoskeleton- and metabolism-related
proteins [30]. This comparative analysis of the proteome
revealed that the percentage of total cytoskeleton-related pro-
teins identified in periodontal ligament fibroblasts (26.5%)
was higher than that in dermal fibroblasts (15%). It was
proposed that this difference is assigned to mechanical
loading and rapid remodelling associated with periodontal
ligament tissue [30].
Assessment of protein expression during differentiation
of PDLSC identified 29 proteins, differentially expressed
during early cementoblastic/osteogenic differentiation [31],
and demonstrated a reduction in expression of cytoskeletal
proteins and their binding partners, potentially attributed
to cytoskeletal rearrangements during differentiation pro-
cesses [32]. Interestingly, higher expression of the calcium-
binding protein Annexin A4 was noted following osteogenic
differentiation. Annexins are thought to play an important
role in osteogenic development including Annexin A2 and
AnnexinA5which are highly expressed in skeletal tissues and
upregulated in osteogenic cultures of MSC [33, 34].
A direct comparison of protein expression profiles
between ovine PDLSC, DPSC, and BMSC identified 58
differentially expressed proteins between at least two MSC
populations, with the expression of 6 proteins upregulated
in PDLSC relative to both DPSC and BMSC, 5 proteins
upregulated in DPSC relative to both PDLSC and BMSC, and
1 protein upregulated in BMSC relative to both PDLSC and
DPSC [35]. An increase in PDLSC expression of heat-shock
protein beta 1, Annexin A3, and Annexin A4 compared to
DPSC and BMSC was thought to relate to high turnover of
periodontal tissues.
The aim of the present study was to determine the surface
expression profile of human PDLSC and to compare the
expression of prospective cell surface markers in human
PDLSC, GF, and keratinocytes (as a source of epithelial cells).
Our findings identified 80 proteins expressed on the surface
of human PDLSC, 32 of which were membrane associated
and four of which were selected for further validation due to
their known association with other MSC-like populations as
a proof-of-principal analysis.These include CD73 and CD90,
well known MSC-associated markers, and Annexin A2 and
SPK1. Annexin A2 is calcium dependent [36–42] and has
been reported to be associated with the stem cell niche [43–
49] and SPK1 has recently been demonstrated to be associated
with the progenitor phenotype of endothelial cells [50]. CD73
and CD90 were highly expressed by human PDLSC and
GF but not by human keratinocytes, indicating that these
antigens could be used as potentialmarkers for distinguishing
mesenchymal from epithelial cell populations. Annexin A2
was demonstratively expressed at the cell surface at low copy
number by human PDLSC and GF, using flow cytometric
analysis, while human keratinocytes lacked any cell surface
expression of Annexin A2. Expression of SPK1 was detected
in all analysed cell types using immunocytochemical analysis.
CD73, originally defined as a lymphocyte differentiation
antigen, functions as a cosignalling molecule on T lympho-
cytes and is required for lymphocyte binding to endothelium
[51]. Expression of CD73 has been demonstrated on various
cell types including lymphocytes, endothelial cells, andMSC.
It is thought to play physiological roles in epithelial ion
and fluid transport, maintaining barrier functions, mediating
endothelial permeability, adapting to hypoxia, and contribut-
ing to microbial responses [52]. CD73 is an extracellular
enzyme that catalyzes the formation of immunosuppres-
sive adenosine by converting adenosine 5󸀠-monophosphate
(AMP) to its bioactive intermediate, adenosine, which in turn
activates adenosine receptors, when released into the extra-
cellular space, and regulates various physiological functions
[52, 53]. Adenosine signalling,modulated byCD39 andCD73
expression, has been highlighted as a novel modulator in the
immunosuppression of T-cell proliferation by MSC [54, 55].
As such, this may be contributory to immunomodulatory
properties of PDLSC [8] and may highlight an avenue for
anti-inflammatory therapy in periodontal disease [4, 56].
The expression of CD90 on PDLSC has been well docu-
mented [56–59]; however, its role in PDLSC function remains
largely unknown. CD90, also known as Thy-1 (thymocyte
differentiation antigen-1), is found to be expressed in various
cell types such as hematopoietic stem/progenitor cells [60],
hepatic stem cells in human fetal liver [61], liver cancer stem
cells [62], neurons, fibroblasts, vascular pericytes, and MSC
[63]. Its expression is developmentally regulated [64] and
remains one of theminimal criteria for defining humanMSC,
proposed by the committee for the International Society for
CellularTherapy (ISCT) [63, 65]. While the biological role of
CD90 is unclear, a number of associated immunological and
nonimmunological functions have been previously addressed
[64]. In addition to its involvement in T-cell activation [64], it
is believed to be associated with many cellular processes and
pathological conditions in a context-dependent manner [63],
including cell-cell and cell-matrix interactions, cell motility,
and thymocyte adhesion to epithelium [64].Moreover, CD90
expression is also associated with fibroblast phenotypes
relevant to wound healing and fibrosis. The differential







Figure 3: The expression of Annexin A2 and sphingosine kinase 1 (SPK1) in fixed and permeabilized (a) human periodontal ligament stem
cells (PDLSC), (b) gingival fibroblasts (GF), and (c) keratinocytes using immunohistochemistry. All cell types studied were positive to anti-
Annexin A2 and anti-SPK1 antibodies. Scale bar = 50 𝜇m.
CD90 expression is associated with cell-extracellular matrix
interactions and cellmigration and, as such, is correlatedwith
distinct cellular morphology [64].
Annexin A2, firstly identified as an intracellular protein,
has since been found extracellularly both in secreted and in
membrane bound form [66]. While Annexin A2 monomer
is largely present in the cytoplasm, the formation of the het-
erotetramer allows its binding to the plasma membrane [67–
70]. Potential roles of extracellular Annexin A2 include plas-
minogen activation, cell-cell adhesion, and immunoglobulin
transport [66]. Increasing evidence has highlighted the roles
of the Annexin family of calcium-dependent, phopholipid-
binding proteins in the mineralization process [36–42] and
found them to be highly expressed in calcifying cartilage and
bone and to serve to initiate mineralization of extracellular
matrix [71]. Previously, it has been suggested that Annexin
members also have the capacity to function in a compen-
satory manner of each other during skeletal development
[72]. In a study investigating intracellular processes involved
inmineralization, the overexpression ofAnnexinA2 has been
shown to increase ALP activity and cartilage and bone for-
mation, while diminished Annexin A2 expression resulted in
decreasedmineralization [38]. Collectively, previous findings
related to Annexins in dental tissues are consistent with their
roles in support of osteogenic differentiation and formation
of minerals [31, 33, 35, 73, 74].
We identified Annexin A2 as one of the cell surface pro-
teins expressed by human PDLSC. Further flow cytometric
analysis showed the surface expression of Annexin A2 at low
copy number by human GF. As a member of the Annexin
family which plays important roles in the mineralization
process [36–42], the low expression of Annexin A2 in
10 Stem Cells International
human GF may be correlated to the fact that human GF
demonstrated limited osteogenic potential when cultured in
osteogenic conditions (data not shown). A recent study [75]
suggested that Annexin A2 regulates adhesion, homing, and
engraftment within stem cell niches at endosteal [43–47] and
vascular [48, 49] sites; hence, we propose that it may be a
potential marker of the PDLSC niche in periodontal tissues.
SPK1, the more characterised of the two SPK isoforms,
enhances cell growth and proliferation and is involved in
immune regulation and tumorigenesis [76]. This highly
conserved lipid kinase catalyzes the phosphorylation of
proapoptotic sphingosine to form antiapoptotic sphingosine-
1-phosphate (S1P) [77] and, as such, is an important cell
fate determinant [78]. S1P is a key sphingolipid metabolite
that regulates various physiological and pathological pro-
cesses such as cell proliferation, differentiation, apoptosis,
migration, invasion, and angiogenesis [78] and is thought
to promote cell growth and proliferation and suppresses
apoptosis [79]. In addition to their roles in regulating cell
proliferation and apoptosis, SPK-S1P-S1P receptors have been
shown to be involved in immune regulation such as immune
cell trafficking, activation, and T-cell differentiation [77].
Multiple studies have demonstrated that SPK and S1P
play important roles in the maintenance of stem cells [76]
including endothelial progenitor cells, rate of endothelial
progenitor cell differentiation [50, 80, 81], neural progenitors
[82], human embryonic stem cells [76, 83], hematopoietic
stem cell [76], and muscle progenitors [84]. Furthermore,
SPK1 is a maker of oncogenic potential, tumour progression,
and cancer prognosis in numerous tissue types [85, 86]. It
is predominantly a cytosolic enzyme, which lacks an obvi-
ous membrane anchoring sequence. However, considerable
evidence has suggested that SPK1 can be translocated to the
plasma membrane upon cell stimulation by growth factors
and cytokines [23–25, 27–29, 83]. The present study initially
identified SPK1 in human PDLSC by proteomic analysis and
SPK1 expression was demonstrated in all cell types examined
by immunocytochemical analysis. However, we were unable
to demonstrate the cell surface expression of this enzyme,
limited by the availability of an SPK1 antibody suitable for
flow cytometry.
5. Conclusion
In summary, this study is the first, to date, to investigate the
cell surface proteome of ex vivo expanded human PDLSC.
In addition to the expression of recognised MSC-associated
cell surface antigens CD73 and CD90, PDLSC were also
found to express two novel cell surface proteins, Annexin
A2 and sphingosine kinase 1. Interestingly, previous studies
have implicated CD73, CD90, Annexin A2, and sphingosine
kinase 1 expression in the maintenance of various stem cell
populations. Importantly, this study found that human skin
epithelial cells lacked the expression of CD73, CD90, and
Annexin A2. These proteomic findings provide the platform
to further define the cell surface protein expression profile of
PDLSC in order to further characterise this cell population
and support development of novel isolation and purification
strategies.
Disclosure
P. Mark Bartold and Stan Gronthos are co-senior authors.
Competing Interests
The authors declare that there are no competing interests
regarding the publication of this paper.
Acknowledgments
This study was partly funded by NHMRC project Grant
APP1043994, fellowship APP1042677, and ADRF Grant
37.2013.
References
[1] T.Graf andM. Stadtfeld, “Heterogeneity of embryonic and adult
stem cells,” Cell Stem Cell, vol. 3, no. 5, pp. 480–483, 2008.
[2] M. Owen and A. J. Friedenstein, “Stromal stem cells: marrow-
derived osteogenic precursors,” Ciba Foundation Symposium,
vol. 136, pp. 42–60, 1988.
[3] S. Gronthos, A. C. W. Zannettino, S. E. Graves, S. Ohta, S. J.
Hay, and P. J. Simmons, “Differential cell surface expression
of the STRO-1 and alkaline phosphatase antigens on discrete
developmental stages in primary cultures of human bone cells,”
Journal of Bone and Mineral Research, vol. 14, no. 1, pp. 47–56,
1999.
[4] B.-M. Seo, M. Miura, S. Gronthos et al., “Investigation of multi-
potent postnatal stem cells from human periodontal ligament,”
The Lancet, vol. 364, no. 9429, pp. 149–155, 2004.
[5] D. Menicanin, K. M. Mrozik, N. Wada et al., “Periodontal-
ligament-derived stem cells exhibit the capacity for long-term
survival, self-renewal, and regeneration of multiple tissue types
in vivo,” StemCells andDevelopment, vol. 23, no. 9, pp. 1001–1011,
2014.
[6] S. C. Chen, V.Marino, S. Gronthos, and P.M. Bartold, “Location
of putative stem cells in human periodontal ligament,” Journal
of Periodontal Research, vol. 41, no. 6, pp. 547–553, 2006.
[7] J. C. Rincon,W. G. Young, and P.M. Bartold, “The epithelial cell
rests of Malassez—a role in periodontal regeneration?” Journal
of Periodontal Research, vol. 41, no. 4, pp. 245–252, 2006.
[8] T. Iwata, M. Yamato, H. Tsuchioka et al., “Periodontal regen-
eration with multi-layered periodontal ligament-derived cell
sheets in a caninemodel,” Biomaterials, vol. 30, no. 14, pp. 2716–
2723, 2009.
[9] P.M. Bartold, S. Shi, and S. Gronthos, “Stem cells and periodon-
tal regeneration,” Periodontology 2000, vol. 40, no. 1, pp. 164–
172, 2006.
[10] C. A. G. McCulloch, “Progenitor cell populations in the peri-
odontal ligament of mice,” Anatomical Record, vol. 211, no. 3,
pp. 258–262, 1985.
[11] C. A. G. McCulloch, E. Nemeth, B. Lowenberg, and A. H.
Melcher, “Paravascular cells in endosteal spaces of alveolar
bone contribute to periodontal ligament cell populations,”
Anatomical Record, vol. 219, no. 3, pp. 233–242, 1987.
[12] S. Yamada, S. Murakami, R. Matoba et al., “Expression profile
of active genes in human periodontal ligament and isolation of
PLAP-1, a novel SLRP family gene,” Gene, vol. 275, no. 2, pp.
279–286, 2001.
Stem Cells International 11
[13] Y. Saito, T. Yoshizawa, F. Takizawa et al., “A cell line with char-
acteristics of the periodontal ligament fibroblasts is negatively
regulated for mineralization and Runx2/Cbfa1/Osf2 activity,
part of which can be overcome by bonemorphogenetic protein-
2,” Journal of Cell Science, vol. 115, no. 21, pp. 4191–4200, 2002.
[14] C. Morsczeck, G. Schmalz, T. E. Reichert, F. Vo¨llner, K. Galler,
and O. Driemel, “Somatic stem cells for regenerative dentistry,”
Clinical Oral Investigations, vol. 12, no. 2, pp. 113–118, 2008.
[15] C. A. McCulloch, “Proteomics for the periodontium: current
strategies and future promise,” Periodontology 2000, vol. 40, no.
1, pp. 173–183, 2006.
[16] Y. Zhang, T. Wang, W. Chen et al., “Differential protein
expression by Porphyromonas gingivalis in response to secreted
epithelial cell components,” Proteomics, vol. 5, no. 1, pp. 198–211,
2005.
[17] Q. Xia, T. Wang, F. Taub et al., “Quantitative proteomics of
intracellular Porphyromonas gingivalis,” Proteomics, vol. 7, no.
23, pp. 4323–4337, 2007.
[18] P. D. Veith, G. H. Talbo, N. Slakeski, and E. C. Reynolds,
“Identification of a novel heterodimeric outer membrane pro-
tein of Porphyromonas gingivalis by two-dimensional gel elec-
trophoresis and peptide mass fingerprinting,” European Journal
of Biochemistry, vol. 268, no. 17, pp. 4748–4757, 2001.
[19] M. J. Somerman, S. Y. Archer, G. R. Imm, and R. A. Foster,
“A comparative study of human periodontal ligament cells and
gingival fibroblasts in vitro,” Journal of Dental Research, vol. 67,
no. 1, pp. 66–70, 1988.
[20] C.Mayrhofer, S. Krieger, G. Allmaier, andD. Kerjaschki, “DIGE
compatible labelling of surface proteins on vital cells in vitro and
in vivo,” Proteomics, vol. 6, no. 2, pp. 579–585, 2006.
[21] P. S. Zilm, A. Mira, C. J. Bagley, and A. H. Rogers, “Effect of
alkaline growth pH on the expression of cell envelope proteins
in Fusobacterium nucleatum,”Microbiology, vol. 156, part 6, pp.
1783–1794, 2010.
[22] A. Gorg, G. Boguth, C. Obermaier, and W. Weiss, “Two-
dimensional electrophoresis of proteins in an immobilized pH
4-12 gradient,” Electrophoresis, vol. 19, no. 8-9, pp. 1516–1519,
1998.
[23] N. Ancellin, C. Colmont, J. Su et al., “Extracellular export of
sphingosine kinase-1 enzyme. Sphingosine 1-phosphate genera-
tion and the induction of angiogenic vascular maturation,”The
Journal of Biological Chemistry, vol. 277, no. 8, pp. 6667–6675,
2002.
[24] J. A. Hengst, J. M. Guilford, T. E. Fox, X. Wang, E. J. Conroy,
and J. K. Yun, “Sphingosine kinase 1 localized to the plasma
membrane lipid raft microdomain overcomes serum depriva-
tion induced growth inhibition,” Archives of Biochemistry and
Biophysics, vol. 492, no. 1-2, pp. 62–73, 2009.
[25] K. E. Jarman, P. A. B. Moretti, J. R. Zebol, and S. M. Pitson,
“Translocation of sphingosine kinase 1 to the plasmamembrane
ismediated by calcium- and integrin-binding protein 1,” Journal
of Biological Chemistry, vol. 285, no. 1, pp. 483–492, 2010.
[26] S. M. Pitson, P. Xia, T. M. Leclercq et al., “Phosphorylation-
dependent translocation of sphingosine kinase to the plasma
membrane drives its oncogenic signalling,” The Journal of
Experimental Medicine, vol. 201, no. 1, pp. 49–54, 2005.
[27] R. V. Stahelin, J. H. Hwang, J.-H. Kim et al., “The mechanism
of membrane targeting of human sphingosine kinase 1,” The
Journal of Biological Chemistry, vol. 280, no. 52, pp. 43030–
43038, 2005.
[28] B. W. Wattenberg, “Role of sphingosine kinase localization in
sphingolipid signaling,” World Journal of Biological Chemistry,
vol. 1, no. 12, pp. 362–368, 2010.
[29] K. W. Young, J. M. Willets, M. J. Parkinson et al.,
“Ca2+/calmodulin-dependent translocation of sphingosine
kinase: role in plasmamembrane relocation but not activation,”
Cell Calcium, vol. 33, no. 2, pp. 119–128, 2003.
[30] E. Reichenberg, M. Redlich, P. Cancemi et al., “Proteomic anal-
ysis of protein components in periodontal ligament fibroblasts,”
Journal of Periodontology, vol. 76, no. 10, pp. 1645–1653, 2005.
[31] L.Wu,X.Wei, J. Ling et al., “Early osteogenic differential protein
profile detected by proteomic analysis in human periodontal
ligament cells,” Journal of Periodontal Research, vol. 44, no. 5,
pp. 645–656, 2009.
[32] L. J. Foster, P. A. Zeemann, C. Li, M. Mann, O. N. Jensen,
andM. Kassem, “Differential expression profiling of membrane
proteins by quantitative proteomics in a human mesenchymal
stem cell line undergoing osteoblast differentiation,” Stem Cells,
vol. 23, no. 9, pp. 1367–1377, 2005.
[33] A.-X. Zhang,W.-H. Yu, B.-F.Ma et al., “Proteomic identification
of differently expressed proteins responsible for osteoblast
differentiation fromhumanmesenchymal stem cells,”Molecular
and Cellular Biochemistry, vol. 304, no. 1-2, pp. 167–179, 2007.
[34] H. J. Sun, Y. Y. Bahk, Y. R. Choi, J. H. Shim, S. H. Han, and
J. W. Lee, “A proteomic analysis during serial subculture and
osteogenic differentiation of human mesenchymal stem cell,”
Journal of Orthopaedic Research, vol. 24, no. 11, pp. 2059–2071,
2006.
[35] K. M. Mrozik, P. S. Zilm, C. J. Bagley et al., “Proteomic
characterization of mesenchymal stem cell-like populations
derived from ovine periodontal ligament, dental pulp, and bone
marrow: analysis of differentially expressed proteins,” StemCells
and Development, vol. 19, no. 10, pp. 1485–1499, 2010.
[36] M. Balcerzak, E. Hamade, L. Zhang et al., “The roles of
annexins and alkaline phosphatase in mineralization process,”
Acta Biochimica Polonica, vol. 50, no. 4, pp. 1019–1038, 2003.
[37] D. C. Genetos, A. Wong, S. Watari, and C. E. Yellowley,
“Hypoxia increases Annexin A2 expression in osteoblastic cells
via VEGF and ERK,” Bone, vol. 47, no. 6, pp. 1013–1019, 2010.
[38] J. M. Gillette and S. M. Nielsen-Preiss, “The role of annexin 2 in
osteoblastic mineralization,” Journal of Cell Science, vol. 117, no.
3, pp. 441–449, 2004.
[39] T. L. Haut Donahue, D. C. Genetos, C. R. Jacobs, H. J.
Donahue, and C. E. Yellowley, “Annexin V disruption impairs
mechanically induced calcium signaling in osteoblastic cells,”
Bone, vol. 35, no. 3, pp. 656–663, 2004.
[40] T. Kirsch, B. Swoboda, and H.-D. Nah, “Activation of annexin II
and V expression, terminal differentiation, mineralization and
apoptosis in human osteoarthritic cartilage,” Osteoarthritis and
Cartilage, vol. 8, no. 4, pp. 294–302, 2000.
[41] D. Pfander, B. Swoboda, and T. Kirsch, “Expression of early and
late differentiation markers (proliferating cell nuclear antigen,
syndecan-3, annexin VI, and alkaline phosphatase) by human
osteoarthritic chondrocytes,” American Journal of Pathology,
vol. 159, no. 5, pp. 1777–1783, 2001.
[42] W. Wang and T. Kirsch, “Retinoic acid stimulates annexin-
mediated growth plate chondrocyte mineralization,” The Jour-
nal of Cell Biology, vol. 157, no. 6, pp. 1061–1069, 2002.
[43] J. Zhang, C. Niu, L. Ye et al., “Identification of the haematopoi-
etic stem cell niche and control of the niche size,” Nature, vol.
425, no. 6960, pp. 836–841, 2003.
12 Stem Cells International
[44] S. Stier, Y. Ko, R. Forkert et al., “Osteopontin is a hematopoietic
stem cell niche component that negatively regulates stem cell
pool size,”The Journal of Experimental Medicine, vol. 201, no. 11,
pp. 1781–1791, 2005.
[45] S. K. Nilsson, H.M. Johnston, G. A.Whitty et al., “Osteopontin,
a key component of the hematopoietic stem cell niche and
regulator of primitive hematopoietic progenitor cells,” Blood,
vol. 106, no. 4, pp. 1232–1239, 2005.
[46] L. M. Calvi, G. B. Adams, K. W. Weibrecht et al., “Osteoblastic
cells regulate the haematopoietic stem cell niche,” Nature, vol.
425, no. 6960, pp. 841–846, 2003.
[47] F. Arai, A. Hirao, M. Ohmura et al., “Tie2/angiopoietin-1
signaling regulates hematopoietic stem cell quiescence in the
bone marrow niche,” Cell, vol. 118, no. 2, pp. 149–161, 2004.
[48] S. T. Avecilla, K.Hattori, B.Heissig et al., “Chemokine-mediated
interaction of hematopoietic progenitors with the bonemarrow
vascular niche is required for thrombopoiesis,”NatureMedicine,
vol. 10, no. 1, pp. 64–71, 2004.
[49] M. J. Kiel, O¨. H. Yilmaz, T. Iwashita, O. H. Yilmaz, C. Ter-
horst, and S. J. Morrison, “SLAM family receptors distinguish
hematopoietic stem and progenitor cells and reveal endothelial
niches for stem cells,” Cell, vol. 121, no. 7, pp. 1109–1121, 2005.
[50] J. M. Barrett, K. A. Parham, J. B. Pippal et al., “Over-expression
of sphingosine kinase-1 enhances a progenitor phenotype in
human endothelial cells,” Microcirculation, vol. 18, no. 7, pp.
583–597, 2011.
[51] B. Zhang, “CD73: a novel target for cancer immunotherapy,”
Cancer Research, vol. 70, no. 16, pp. 6407–6411, 2010.
[52] S. P. Colgan, H. K. Eltzschig, T. Eckle, and L. F. Thompson,
“Physiological roles for ecto-5󸀠-nucleotidase (CD73),” Puriner-
gic Signalling, vol. 2, no. 2, pp. 351–360, 2006.
[53] P. A. Beavis, J. Stagg, P. K. Darcy, and M. J. Smyth, “CD73: a
potent suppressor of antitumor immune responses,” Trends in
Immunology, vol. 33, no. 5, pp. 231–237, 2012.
[54] C. Sattler, M. Steinsdoerfer, M. Offers et al., “Inhibition of T-cell
proliferation bymurinemultipotent mesenchymal stromal cells
ismediated byCD39 expression and adenosine generation,”Cell
Transplantation, vol. 20, no. 8, pp. 1221–1230, 2011.
[55] F. Saldanha-Araujo, F. I. S. Ferreira, P. V. Palma et al., “Mes-
enchymal stromal cells up-regulate CD39 and increase adeno-
sine production to suppress activated T-lymphocytes,” StemCell
Research, vol. 7, no. 1, pp. 66–74, 2011.
[56] N. Wada, D. Menicanin, S. Shi, P. M. Bartold, and S. Gron-
thos, “Immunomodulatory properties of human periodontal
ligament stem cells,” Journal of Cellular Physiology, vol. 219, no.
3, pp. 667–676, 2009.
[57] T. Kato, K. Hattori, T. Deguchi et al., “Osteogenic potential of
rat stromal cells derived from periodontal ligament,” Journal of
Tissue Engineering and Regenerative Medicine, vol. 5, no. 10, pp.
798–805, 2011.
[58] A. Tomokiyo, H. Maeda, S. Fujii et al., “A multipotent clonal
human periodontal ligament cell line with neural crest cell
phenotypes promotes neurocytic differentiation, migration,
and survival,” Journal of Cellular Physiology, vol. 227, no. 5, pp.
2040–2050, 2012.
[59] O. Trubiani, S. F. Zalzal, R. Paganelli et al., “Expression profile
of the embryonic markers nanog, OCT-4, SSEA-1, SSEA-4, and
frizzled-9 receptor in human periodontal ligament mesenchy-
mal stem cells,” Journal of Cellular Physiology, vol. 225, no. 1, pp.
123–131, 2010.
[60] C. M. Baum, I. L. Weissman, A. S. Tsukamoto, A.-M. Buckle,
and B. Peault, “Isolation of a candidate human hematopoietic
stem-cell population,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 89, no. 7, pp. 2804–
2808, 1992.
[61] N. M. Masson, I. S. Currie, J. D. Terrace, O. J. Garden, R. W.
Parks, and J. A. Ross, “Hepatic progenitor cells in human fetal
liver express the oval cell marker Thy-1,” American Journal of
Physiology—Gastrointestinal and Liver Physiology, vol. 291, no.
1, pp. G45–G54, 2006.
[62] Z. F. Yang, D. W. Ho, M. N. Ng et al., “Significance of CD90+
cancer stem cells in human liver cancer,” Cancer Cell, vol. 13,
no. 2, pp. 153–166, 2008.
[63] J. E. Bradley, G. Ramirez, and J. S. Hagood, “Roles and
regulation of Thy-1, a context-dependent modulator of cell
phenotype,” BioFactors, vol. 35, no. 3, pp. 258–265, 2009.
[64] S.M.M.Haeryfar andD.W.Hoskin, “Thy-1:more than amouse
pan-T cell marker,” Journal of Immunology, vol. 173, no. 6, pp.
3581–3588, 2004.
[65] M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal crite-
ria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position statement,”
Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.
[66] D. A. Siever and H. P. Erickson, “Extracellular annexin II,”
International Journal of Biochemistry and Cell Biology, vol. 29,
no. 11, pp. 1219–1223, 1997.
[67] N. Zobiack, V. Gerke, and U. Rescher, “Complex formation and
submembranous localization of annexin 2 and S100A10 in live
HepG2 cells,” FEBS Letters, vol. 500, no. 3, pp. 137–140, 2001.
[68] J. R. Glenney Jr., “Co-precipitation of intestinal p36 with a 73K
protein and a high molecular weight factor,” Experimental Cell
Research, vol. 162, no. 1, pp. 183–190, 1986.
[69] V. Gerke and K.Weber, “Identity of p36K phosphorylated upon
Rous sarcoma virus transformation with a protein purified from
brush borders; calcium-dependent binding to non-erythroid
spectrin and F-actin,”The EMBO Journal, vol. 3, no. 1, pp. 227–
233, 1984.
[70] C.Thiel, M. Osborn, and V. Gerke, “The tight association of the
tyrosine kinase substrate annexin II with the submembranous
cytoskeleton depends on intact p11- and Ca2+-binding sites,”
Journal of Cell Science, vol. 103, no. 3, pp. 733–742, 1992.
[71] H. C. Anderson, “Molecular biology of matrix vesicles,”Clinical
Orthopaedics and Related Research, no. 314, pp. 266–280, 1995.
[72] B. Brachvogel, J. Dikschas, H. Moch et al., “Annexin A5 is
not essential for skeletal development,” Molecular and Cellular
Biology, vol. 23, no. 8, pp. 2907–2913, 2003.
[73] K. Yuan, J.-S. Huang, C.-W. Hsu, and I.-J. Hung, “A
mineralization-associated membrane protein plays a role
in the biological functions of the peptide-coated bovine
hydroxyapatite,” Journal of Periodontal Research, vol. 42, no. 5,
pp. 420–428, 2007.
[74] D. Bozic, L. Grgurevic, I. Erjavec et al., “The proteome and
gene expression profile of cementoblastic cells treated by bone
morphogenetic protein-7 in vitro,” Journal of Clinical Periodon-
tology, vol. 39, no. 1, pp. 80–90, 2012.
[75] Y. Jung, J. Wang, J. Song et al., “Annexin II expressed by
osteoblasts and endothelial cells regulates stem cell adhesion,
homing, and engraftment following transplantation,”Blood, vol.
110, no. 1, pp. 82–90, 2007.
[76] A. Pe´bay, C. S. Bonder, and S.M. Pitson, “Stem cell regulation by
lysophospholipids,” Prostaglandins and Other Lipid Mediators,
vol. 84, no. 3-4, pp. 83–97, 2007.
Stem Cells International 13
[77] H. Chi, “Sphingosine-1-phosphate and immune regulation:
trafficking and beyond,”Trends in Pharmacological Sciences, vol.
32, no. 1, pp. 16–24, 2011.
[78] A. Olivera and S. Spiegel, “Sphingosine kinase: a mediator
of vital cellular functions,” Prostaglandins and Other Lipid
Mediators, vol. 64, no. 1–4, pp. 123–134, 2001.
[79] S. Spiegel, O. Cuvillier, L. C. Edsall et al., “Sphingosine-1-
phosphate in cell growth and cell death,”Annals of the New York
Academy of Sciences, vol. 845, pp. 11–8, 1998.
[80] V. Limaye, X. Li, C. Hahn et al., “Sphingosine kinase-1 enhances
endothelial cell survival through a PECAM-1-dependent acti-
vation of PI-3K/Akt and regulation of Bcl-2 family members,”
Blood, vol. 105, no. 8, pp. 3169–3177, 2005.
[81] C. S. Bonder, W. Y. Sun, T. Matthews et al., “Sphingosine kinase
regulates the rate of endothelial progenitor cell differentiation,”
Blood, vol. 113, no. 9, pp. 2108–2117, 2009.
[82] H. Meng, Y. Yuan, and V. M. Lee, “Loss of Sphingosine kinase
1/S1P signaling impairs cell growth and survival of neurons and
progenitor cells in the developing sensory ganglia,” PLoS ONE,
vol. 6, no. 11, Article ID e27150, 2011.
[83] A. Pe´bay, R. C. B. Wong, S. M. Pitson et al., “Essential roles of
sphingosine-1-phosphate and platelet-derived growth factor in
the maintenance of human embryonic stem cells,” Stem Cells,
vol. 23, no. 10, pp. 1541–1548, 2005.
[84] Y. Nagata, T. A. Partridge, R. Matsuda, and P. S. Zammit, “Entry
of muscle satellite cells into the cell cycle requires sphingolipid
signaling,” The Journal of Cell Biology, vol. 174, no. 2, pp. 245–
253, 2006.
[85] P. Xia, J. R. Gamble, L. Wang et al., “An oncogenic role of
sphingosine kinase,” Current Biology, vol. 10, no. 23, pp. 1527–
1530, 2000.
[86] D. Shida, K. Takabe, D. Kapitonov, S. Milstien, and S. Spiegel,
“Targeting SphK1 as a new strategy against cancer,” Current
Drug Targets, vol. 9, no. 8, pp. 662–673, 2008.










Hindawi Publishing Corporation 
http://www.hindawi.com













Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
